Whither advanced therapy medicinal products?

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 6, 2013, Pages 449-452

  Smith, Mark D ^a   Brune, Jan C ^a   Wildemann, Britt ^b   Pruss, Axel ^b  

^a Deutsches Institut für Zell und Gewebeersatz GGmbH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROCYTE IMPLANT;

ACELLULAR DERMAL MATRIX; BLOOD TRANSFUSION; CELL THERAPY; CELL TYPE; CERTIFICATION; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE FACILITY; HUMAN; LAW; MEDICAL DEVICE; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REGENERATIVE MEDICINE; REIMBURSEMENT; THERAPY; TISSUE ENGINEERING; ADVANCED THERAPY MEDICINAL PRODUCT; GENE THERAPY; PHARMACEUTICAL CARE; RISK;

EID: 84896524410     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000356514     Document Type: Note

References (22)

1. European Union: Regulation (EC) No 1394/2007 of the European Parliament and of the Council. 2007.
2. European Union: Commission Directive 2009/120/EC. 2009.
3. European Union: Council Directive 93/42/EEC. 2008.
4. European Union: Directive 2004/23/EC of the European Parliament and of the Council. 2004.
5. U.S. Food and Drug Administration: Guidance for Industry: Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)-Small Entity Compliance Guide.Available from: www.fda.gov/BiologicsBloodVaccines/ Guidance-ComplianceRegulatoryInformation/Guidances/Tissue/ucm073366.htm.
6. Maciulaitis R, D'Apote L, Buchanan A, Pioppo L, Schneider CK: Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther 2009; 20:479-482.
7. Notorious stem cell therapy centre closes in Germany. Nature News Blog. http://blogs.nature.com/news/2011/05/notorious-stem-cell-therapy-ce-1. html.
8. Zylka-Menhorn V: XCell-Center: Das Dilemma der Übergangsfrist. Dtsch Ärztebl 2010;107:A-2499/B-2171/C-2127.
9. Qiu J: Trading on hope. Nat Biotechnol 2009;27: 790-792.
10. European Medicines Agency: Fee Reductions/Deferrals for micro, small and medium-sized enterprises (SMEs). 2005. Available from: www.ema.europa. eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/ WC500004165.pdf.
11. European Medicines Agency: Minutes of the 78th meeting of the Management Board. 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/ Minutes/2013/03/WC500140773.pdf.
12. European Union: Council Regulation (EC) No 297/95. 2006.
13. European Medicines Agency: Explanatory note on fees payable to the European Medicines Agency. 2013. Available from: www.ema.europa.eu/docs/en-GB/ document-library/Other/2012/03/WC500124904.pdf.
14. European Medicines Agency: CAT monthly report of application procedures, guidelines and related documents on advanced therapies. 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/Committee-meeting-report/2013/03/ WC500140711.pdf.
15. European Medicines Agency: Procedural advice on the evaluation of advanced therapy medicinal product in accordance with Article 8 of Regulation (EC) No 1394/2007. 2009. Available from: www. ema.europa.eu/docs/en-GB/document- library/Regulatory-and-procedural-guideline/2010/02/WC500070340.pdf.
16. Withdrawal of the marketing authorisation application for OraNera (autologous oral mucosal epithelial cells). Available from: www.ema.europa.eu/ docs/en-GB/document-library/Medicine-QA/2013/03/WC500140698.pdf.
17. Withdrawal of the marketing authorisation application for Hyalograft C autograft (characterised viable autologous chondrocytes expanded in vitro, seeded and cultured on a hyaluronan-based scaffold). Available from: www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2013/02/WC500139258. pdf.
18. European Medicines Agency-Find medicine-ChondroCelect. Available from: www.ema.europa. eu/ema/index.jsp?curl = pages/medicines/human/medicines/000878/ human-med-000698.jsp and mid = WC0b01ac058001d124.
19. European Medicines Agency-Find medicine-Glybera. Available from: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002145/ human-med-001480.jsp and mid = WC0b01ac058001d124.
20. European Medicines Agency-Find medicine-Maci. Available from: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002522/ human-med-001660.jsp and mid = WC-0b01ac058001d124.
21. European Medicines Agency-Human medicines-Provenge. Available from: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002513/ smops/Positive/human-smop-000538. jsp and mid = WC0b01ac058001d127.
22. European Medicines Agency: Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. Available from: www.ema.europa.eu/docs/en-GB/document-library/Report/2013/07/WC500145301. pdf.